ArticlePublished 2010
Updates in Pancreatic Neuroendocrine Carcinoma Highlights from the
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Pancreatic neuroendocrine tumors display a range of clinical presentations and outcomes. Surgical resection remains the only potentially curative approach for primary tumors, and is also associated with a survival benefit for hepatic metastases as well. Data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting this year suggest that targeted agents may also play a role in advanced disease. Sunitinib, which targets VEGF-1, 2 and 3 and PDGF seems to be a well tolerated treatment for advanced tumors. The mTOR inhibitor everolimus when combined with the VEGF inhibitor bevacizumab, resulted in measurable responses. The combination of bevacizumab and cytotoxic chemotherapy also shows potential.
Subjects
Gastroenterology & HepatologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of the Pancreas
- SubjectGastroenterology & Hepatology
- BylineArticles whose byline prints “Muhammad Wasif Saif”
- BylineArticles whose byline prints “Susan Alsamarai”
- BylineArticles whose byline prints “Steven K Libutti”